As of Dec 09
| +0.28 / +3.16%|
The 5 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 9.00. The median estimate represents a +20.22% increase from the last price of 9.15.
The current consensus among 5 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.